INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
NCT ID: NCT02977780
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
460 participants
INTERVENTIONAL
2017-02-09
2028-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The drugs involved in this study are :
* Abemaciclib (arm is currently closed to accrual)
* Temozolomide (temodar)
* Neratinib (arm is currently closed to accrual)
* CC115 (arm is currently closed to accrual)
* QBS10072S
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this research study, the investigators are looking to compare the effects, good and bad, of the standard of care with the three investigational agent sub-studies Abemaciclib, Neratinib, CC115, QBS10072S to help people with Glioblastoma including the specific molecular changes in the genes and proteins.
The FDA has approved Temozolomide (temodar) as a treatment for this disease, however the FDA has not approved Abemaciclib, CC115, Neratinib, QBS10072S for any diseases.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
The drugs involved in this study are:
Abemaciclib: start date= 12/9/2017 Temozolomide (temodar): start date= 12/9/2017 Neratinib: start date= 12/9/2017 CC115: start date= 12/9/2017 QBS10072S: start date= 12/13/2022
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Temozolomide
* Daily Radiation for a maximum of 49 days.
* Temozolomide will be administered orally on a daily dosing schedule
* Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy
* Temozolomide will also be administered post radiation for up to 6 cycles (5 days/cycle)
Temozolomide
Temzolomide capsules
Neratinib with Temozolomide
* Daily Radiation for a maximum of 49 days.
* Temozolomide will be administered orally on a daily dosing schedule
* Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy
* Neratinib will be taken post radiation at a daily oral pre-determine dose
Temozolomide
Temzolomide capsules
Neratinib
Neratinib tablets
QBS10072S
Daily Radiation for a maximum of 49 days.
QBS10072S will be administered on Day 1 of Radiation Treatment
QBS10072S will be administered post- radiation for up to 6 cycles
QBS10072S
QBS10072S administered intravenously
Abemaciclib with Temozolomide
* Daily Radiation for a maximum of 49 days.
* Temozolomide will be administered orally on a daily dosing schedule during radiation
* Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy
* Abemaciclib will be taken post radiation at a twice daily oral pre-determined dose
Temozolomide
Temzolomide capsules
Abemaciclib
Abemaciclib tablets
CC-115
* Twice daily oral dosing of CC-115
* Daily Radiation for a maximum of 49 days
* CC115 will also be taken twice daily post radiation
CC-115
CC-115 tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Temozolomide
Temzolomide capsules
Neratinib
Neratinib tablets
QBS10072S
QBS10072S administered intravenously
Abemaciclib
Abemaciclib tablets
CC-115
CC-115 tablets
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants may have had prior surgery for glioblastoma or gliosarcoma but no systemic or radiation therapy.
* Age ≥ 18 years.
* Karnofsky performance status ≥60
* Participants must have normal organ and marrow function as defined below:
* Leukocytes ≥3,000/mL
* Absolute neutrophil count ≥1,500/mL
* Platelets ≥100,000/mL
* Hemoglobin ≥ 9g/dl
* Total bilirubin within normal institutional limits (except for participant's with Gilbert's disease)
* AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional upper limit of normal
* Creatinine ≤ institutional upper limit of normal OR
* Creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
* Potassium within normal institutional range, or correctable with supplements
* Serum amylase ≤ 1.5 x institutional upper limit of normal
* Serum lipase ≤ 1.5 x institutional upper limit of normal
* INR \< 2.0
* PTT ≤ institutional upper limit of normal, unless receiving therapeutic low molecular weight heparin
* Must be able to swallow pills.
* Participants must plan to begin radiation therapy 14-42 days after surgical resection.
* Immunohistochemically negative for IDH1 R132H mutation.
* Evidence that the tumor MGMT promoter is unmethylated by standard of care assays.
* Genotyping data available or in process (data must be available at time of initial registration if randomization probabilities differ across biomarker subgroups as determined by the DFCI Coordinating Center) to assign biomarker subgroups through whole exome sequencing, whole genome copy number analysis, or a combination as described in Section 9.1.
* MRI with gadolinium should be obtained within 21 days prior to beginning treatment. Patients without measurable disease are eligible. Participants must be able to undergo MRIs (CTs are not allowed for response assessment on study).
* The effects of the experimental agents used in this study on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential (women who are not free from menses for \> 2 years, post hysterectomy/oophorectomy, or surgically sterilized) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation unless otherwise specified in sub-study that the participant is randomized to. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
* For women of child bearing potential (women who are not free from menses for \> 2 years, post hysterectomy/oophorectomy, or surgically sterilized) a negative serum pregnancy test must be documented prior to initial registration.
* Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria
* Planned major surgery.
* Participants who are receiving any other investigational agents.
* Participants who have had any prior cranial radiotherapy.
* Planned use of Optune™.
* History of a different malignancy, unless (a) have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence of that malignancy, and/or (b) malignancy was cervical cancer in situ, superficial bladder cancer or basal cell or squamous cell carcinoma of the skin, and malignancy has been treated. Patients who meet the above listed criteria and are only on preventative treatment will be deemed eligible.
* History of intratumoral or peritumoral hemorrhage if deemed significant by the treating physician.
* Impaired cardiac function or clinically significant cardiac diseases, including any of the following:
* Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association functional classification of ≥2), unstable angina, myocardial infarction within 12 months of enrollment, or ventricular arrhythmia.
* Known history of congenital QT prolongation or Torsade de pointes (TdP).
* Complete left bundle branch or bifascicular block.
--QTc interval \> 450 ms for men or \> 470 ms for women.
* Persistent or history of clinically meaningful ventricular arrhythmias or atrial fibrillation.
* Unstable pectoris or myocardial infarction ≤ 3 months prior to starting study treatment.
* Uncontrolled hypertension (blood pressure ≥ 160/95 mmHg).
* Other clinically significant heart disease such as congestive heart failure requiring treatment.
* Uncontrolled diabetes mellitus, or subjects with either of the following:
* Fasting blood glucose (FBG defined as fasting for at least 8 hours) ≥ 200 mg/dL (7.0 mmol/L), or
* HbA1c ≥ 8%
* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, chronic liver disease (e.g., cirrhosis, hepatitis), chronic renal disease, pancreatitis, chronic pulmonary disease, or psychiatric illness/social situations that would limit compliance with study requirements. Subjects must be free of any clinically relevant disease (other than glioma) that would, in the treating investigator's opinion, interfere with the conduct of the study or study evaluations.
* Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNS \[qualitative\] is detected).
* Known acute or chronic pancreatitis.
* Participants with active diarrhea ≥ CTCAE grade 2 despite medical management.
* Active infection requiring antibiotics.
* Pregnant or breastfeeding.
* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or extensive small bowel resection). Participants with unresolved diarrhea ≥ CTCAE grade 2 will be excluded as previously indicated.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the experimental agents or other agents used in study.
* Participants taking an enzyme-inducing anti-epileptic drug (EIAED): phenobarbital, phenytoin, fosphenytoin, primidone, carbamazepine, oxcarbazepine, eslicarbazepine, rufinamide, and felbamate. Participant must be off any EIAEDs for at least 7 days prior to planned start of study treatment. A list of EIAED and other inducers of CYP3A4 is provided. Among non-EIAED, caution is recommended with use of valproic acid due to potential for drug interaction.
* Participants taking a drug known to be strong inhibitors or inducers of isoenzyme CYP3A. Participant must be off CYP3A inhibitors and inducers for at least 7 days prior to planned start of study treatment. NOTE: participants must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to planned start of study treatment and during the entire study treatment period due to potential CYP3A4 interaction.
* Current use of herbal preparations/medications, including but not limited to: St. John's wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, ginseng. Participants should stop using these herbal medications 7 days prior to planned start of study treatment.
* Current use of warfarin sodium or any other coumadin-derivative anticoagulant. Participant must be off Coumadin-derivative anticoagulants for at least 7 days prior to planned start of study treatment. Low molecular weight heparin and factor Xa inhibitors are allowed.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Celgene
INDUSTRY
Puma Biotechnology, Inc.
INDUSTRY
Accelerate Brain Cancer Cure
OTHER
Quadriga Biosciences, Inc.
INDUSTRY
Patrick Wen, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Patrick Wen, MD
Director, Center for Neuro-Oncology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patrick Y Wen, MD
Role: PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Mayo Clinic
Rochester, Minnesota, United States
Columbia University Medical Center
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Cleveland Clinic
Cleveland, Ohio, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Lifespan / Rhode Island Hospital
Providence, Rhode Island, United States
UT MD Anderson Cancer Center
Houston, Texas, United States
Huntsman Cancer Institute
Salt Lake City, Utah, United States
University of Virginia Health System
Charlottesville, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Isabel Arrillaga-Romany, MD PhD
Role: primary
Patrick Y. Wen, MD
Role: primary
Lisa Doherty, NP
Role: backup
Thomas Kaley, MD
Role: primary
Jan Drappatz, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Rahman R, Trippa L, Lee EQ, Arrillaga-Romany I, Fell G, Touat M, McCluskey C, Wiley J, Gaffey S, Drappatz J, Welch MR, Galanis E, Ahluwalia MS, Colman H, Nabors LB, Hepel J, Elinzano H, Schiff D, Chukwueke UN, Beroukhim R, Nayak L, McFaline-Figueroa JR, Batchelor TT, Rinne ML, Kaley TJ, Lu-Emerson C, Mellinghoff IK, Bi WL, Arnaout O, Peruzzi PP, Haas-Kogan D, Tanguturi S, Cagney D, Aizer A, Doherty L, Lavallee M, Fisher-Longden B, Dowling S, Geduldig J, Watkinson F, Pisano W, Malinowski S, Ramkissoon S, Santagata S, Meredith DM, Chiocca EA, Reardon DA, Alexander BM, Ligon KL, Wen PY. Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. J Clin Oncol. 2023 Dec 20;41(36):5524-5535. doi: 10.1200/JCO.23.00493. Epub 2023 Sep 18.
Groot J, Ott M, Wei J, Kassab C, Fang D, Najem H, O'Brien B, Weathers SP, Matsouka CK, Majd NK, Harrison RA, Fuller GN, Huse JT, Long JP, Sawaya R, Rao G, MacDonald TJ, Priebe W, DeCuypere M, Heimberger AB. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol. 2022 Jun 1;11(2):CNS87. doi: 10.2217/cns-2022-0005. Epub 2022 May 16.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-443
Identifier Type: -
Identifier Source: org_study_id